Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment…

Continue reading here:
Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment...

Related Posts

Comments are closed.